High plasma levels of COL10A1 are associated with advanced tumor stage in gastric cancer patients

Table 1 Clinical and pathological details of patients included in the study, n (%)

Characteristics	Patients (n = 49)
Age (yr): Median	61
Sex
Men	33 (67.35)
Women	16 (32.65)
Tumor size
≤ 5 cm	20 (40.8)
5-7 cm	17 (34.7)
> 7 cm	12 (24.5)
Site of tumor
Upper stomach	3 (6.1)
Middle stomach	31 (63.3)
Lower stomach	15 (30.6)
Type of gastrectomy
Total	34 (69.4)
Subtotal	15 (30.6)
Pathological tumor stage
T1	2 (4.1)
T2	19 (38.7)
T3	21 (42.9)
T4	7 (14.3)
Pathological nodal stage
N0	6 (12.2)
N1	24 (49)
N2	15 (30.6)
N3	4 (8.2)
AJCC stage
IB	1 (2)
II	14 (28.6)
IIIA	15 (30.6)
IIIB	5 (10.2)
IV	14 (28.6)
Histological type
Differentiated	5 (10.2)
Undifferentiated	44 (89.8)

Table 2 Evaluation of the detection value of COL10A1 in the diagnosis of gastric cancer patients.

	AUC	P value	Cut-off values (ng/mL)	Sensitivity	Specificity
GC vs CFC	0.9171 (0.8443 to 0.9899)	0.0002	113.3	87.76% (75.76%-94.27%)	100% (67.56%-100.0%)
Early stage GC vs CFC	0.8789 (0.7385 to 1.000)	0.003	118.1	81.25% (56.99%-93.41%)	100% (67.56%-100.0%)
Advanced stage GC vs CFC	1.000 (1.000 to 1.000)	0.0001	113.3	100% (78.47%-100.0%)	100% (67.56%-100.0%)
Early stage vs Advanced stage	0.7768 (0.5977 to 0.9558)	0.0100	225.3	78.57% (52.41%-92.43%)	81.25% (56.99%-93.41%)

95%CI was given in brackets for each group. GC: Gastric cancer; CFC: Cancer-free controls; AUC: Area under the Receiver operating characteristic curve; Early stage: AJCC stage II; Advanced stage: AJCC stage IV.